✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Jiangsu Hengrui Pharmaceuticals Co Ltd

Common Name
Jiangsu Hengrui Pharmaceuticals
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
20,238
Ticker
600276
Exchange
SHANGHAI STOCK EXCHANGE
Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a prominent player in the biopharmaceutical industry, focused on the research, development, manufacturing, and marketing of a comprehensive range of medica...

Jiangsu Hengrui Pharmaceuticals's GHG Emissions Data Preview

In 2024, Jiangsu Hengrui Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Jiangsu Hengrui Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Unspecified Calculation Method
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Jiangsu Hengrui Pharmaceuticals’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2021, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=600276&reporting_period=2024"

Verified Sources Behind Jiangsu Hengrui Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Jiangsu Hengrui Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Jiangsu Hengrui Pharmaceuticals's ESG Report 2024
b. Jiangsu Hengrui Pharmaceuticals's ESG Report 2023

Insights into Jiangsu Hengrui Pharmaceuticals's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Jiangsu Hengrui Pharmaceuticals amounted to 257,897.24 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Jiangsu Hengrui Pharmaceuticals increased by 23.82%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Jiangsu Hengrui Pharmaceuticals's Scope 1 Emissions Over Time

202120222023202402.5 k5 k7.5 k10 ktCO2e-32%-18%+74%
  • Total Scope 1
  • Year-over-Year Change

What are Jiangsu Hengrui Pharmaceuticals's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Jiangsu Hengrui Pharmaceuticals were 8,516.6 metric tons of CO₂ equivalent (tCO₂e).a

Has Jiangsu Hengrui Pharmaceuticals reduced its Scope 1 emissions over time?

Since 2021, Jiangsu Hengrui Pharmaceuticals's Scope 1 emissions have decreased by 3.63%, reflecting a declining long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Jiangsu Hengrui Pharmaceuticals's Scope 1 emissions increased by 73.88%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Jiangsu Hengrui Pharmaceuticals's Scope 2 emissions?

In 2024, Jiangsu Hengrui Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 249,380.64 tCO₂e without specifying the calculation method.a

Has Jiangsu Hengrui Pharmaceuticals reduced its Scope 2 emissions over time?

Since 2021, Jiangsu Hengrui Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Jiangsu Hengrui Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.ab

Compared to the previous year (2023), Jiangsu Hengrui Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) rose by 22.62% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya

What methodology does Jiangsu Hengrui Pharmaceuticals use for Scope 2 reporting?

In 2024, Jiangsu Hengrui Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a

Jiangsu Hengrui Pharmaceuticals's Scope 2 Emissions Over Time

2021202220232024065 k130 k195 k260 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Jiangsu Hengrui Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Jiangsu Hengrui Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 8,516.6 tCO₂e and total revenues of USD 3,835 millions. This translates into an emissions intensity of 2.22 tCO₂e per millions USD.a

Jiangsu Hengrui Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers

102005,000100,0002,000,000Scope 1 Emissions (tCO2e)2202002,00010,000Revenues (Millions of USD)ZCCHPADSDCZZZhejiang NhuYear: 2024Scope 1: 765,023 tCO2eRevenue: $M 2,961Scope 1 Intensity: 258.37 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MCCCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MHumanwell Healthcare GroupYear: 2024Scope 1: 19,500 tCO2eRevenue: $M 3,485Scope 1 Intensity: 5.60 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 945Scope 1 Intensity: 11.38 tCO2e/$MLivzon Pharmaceutical GroupYear: 2024Scope 1: 194,441 tCO2eRevenue: $M 1,619Scope 1 Intensity: 120.13 tCO2e/$MCCChangchun High-TechYear: 2023Scope 1: 61,590 tCO2eRevenue: $M 2,050Scope 1 Intensity: 30.05 tCO2e/$MHansoh Pharmaceutical GroupYear: 2024Scope 1: 13,163 tCO2eRevenue: $M 1,830Scope 1 Intensity: 7.19 tCO2e/$MHHHuadong MedicineYear: 2024Scope 1: 15,595 tCO2eRevenue: $M 5,742Scope 1 Intensity: 2.72 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MPPPorton Pharma SolutionsYear: 2024Scope 1: 18,865 tCO2eRevenue: $M 413Scope 1 Intensity: 45.71 tCO2e/$MBioKangtaiYear: 2023Scope 1: 15,952 tCO2eRevenue: $M 489Scope 1 Intensity: 32.60 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2023Scope 1: 48,815 tCO2eRevenue: $M 777Scope 1 Intensity: 62.81 tCO2e/$MYunnan Baiyao GroupYear: 2024Scope 1: 15,079 tCO2eRevenue: $M 5,485Scope 1 Intensity: 2.75 tCO2e/$MConsun Pharmaceutical GroupYear: 2023Scope 1: 54,210 tCO2eRevenue: $M 398Scope 1 Intensity: 136.27 tCO2e/$MAAApeloa PharmaceuticalYear: 2024Scope 1: 10,400 tCO2eRevenue: $M 1,647Scope 1 Intensity: 6.31 tCO2e/$MDDDong-E-E-JiaoYear: 2023Scope 1: 15,659 tCO2eRevenue: $M 663Scope 1 Intensity: 23.60 tCO2e/$MFosun PharmaYear: 2024Scope 1: 184,016 tCO2eRevenue: $M 5,627Scope 1 Intensity: 32.70 tCO2e/$MSSSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 286Scope 1 Intensity: 159.27 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MHua MedicineYear: 2023Scope 1: 19 tCO2eRevenue: $M 12Scope 1 Intensity: 1.63 tCO2e/$MHepalinkYear: 2024Scope 1: 18,284 tCO2eRevenue: $M 724Scope 1 Intensity: 25.27 tCO2e/$MDDDa Ren TangYear: 2023Scope 1: 5,902 tCO2eRevenue: $M 1,157Scope 1 Intensity: 5.10 tCO2e/$MCCChina Resources SanjiuYear: 2024Scope 1: 55,312 tCO2eRevenue: $M 3,784Scope 1 Intensity: 14.62 tCO2e/$MEdding Genor Group HoldingsYear: 2022Scope 1: 18 tCO2eRevenue: $M 3Scope 1 Intensity: 7.17 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2024Scope 1: 8,517 tCO2eRevenue: $M 3,835Scope 1 Intensity: 2.22 tCO2e/$M

How does Jiangsu Hengrui Pharmaceuticals's GHG emissions intensity compare to its peers?

In 2024, Jiangsu Hengrui Pharmaceuticals reported a Scope 1 emissions intensity of 2.22 tCO₂e per millions USD. Compared to the peer group median of 25.27, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Jiangsu Hengrui Pharmaceuticals rank on GHG emissions intensity within its industry?

In 2024, Jiangsu Hengrui Pharmaceuticals ranked 2 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Jiangsu Hengrui Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers.a

Want Full Access to Jiangsu Hengrui Pharmaceuticals's GHG Emissions Dataset?
Start 30-Day Free Trial